Clinical Trials Logo

Chronic Idiopathic Constipation clinical trials

View clinical trials related to Chronic Idiopathic Constipation.

Filter by:

NCT ID: NCT01372423 Completed - Clinical trials for Chronic Idiopathic Constipation

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the clinical equivalence and safety of the Test formulation of lubiprostone 24 mcg capsules compared to the marketed formulation AMITIZA® (lubiprostone) 24 mcg capsules (Sucampo Pharmaceuticals, Inc.) in patients with confirmed chronic idiopathic constipation.

NCT ID: NCT01053962 Completed - Clinical trials for Chronic Idiopathic Constipation

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

CIC
Start date: March 2010
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic idiopathic constipation.

NCT ID: NCT00761254 Terminated - Nausea Clinical Trials

Domperidone for Relief of Gastrointestinal Disorders

Start date: August 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to make Domperidone available to patients with gastrointestinal disorders who have failed standard therapy and who might benefit from it.

NCT ID: NCT00511771 No longer available - Clinical trials for Chronic Idiopathic Constipation

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation

Start date: n/a
Phase: N/A
Study type: Expanded Access

To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.